TORONTO, Ontario, July 2, 2020 – Takeda Canada Inc. today announced the completion of the Canadian amalgamation with Shire Pharma Canada ULC, creating a portfolio of innovative treatments and establishing itself as a leader across several therapeutic areas.
Headquartered in Toronto with more than 350 employees across the country, the amalgamation marks the completion of the integration which began in January 2019. As a fully integrated company, Takeda Canada provides innovative medicines in the areas of Oncology, Rare Diseases, Gastroenterology, Neuroscience and Plasma-Derived Therapies, delivering highly-innovative medicines to Canadian patients.
“The transition to creating One Takeda in Canada couldn’t have happened without the dedication and commitment of our employees who work tirelessly to ensure we leverage our collective strengths and expertise,” said Gamze Yüceland, General Manager, Takeda Canada. “We’re incredibly excited about the potential that bringing these two companies together creates, but even more importantly what it represents for Canadian patients.”
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced the completion of its acquisition of Shire plc (“Shire”) in January 2019, becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. Takeda now has an attractive, expanded geographic footprint and leading position in Japan and the U.S., bringing its highly-innovative medicines to approximately 80 countries/regions with dedicated employees worldwide.
“The amalgamation in Canada is a significant milestone for Takeda in one of our key markets worldwide,” said Giles Platford, President, Europe and Canada Business Unit. “I am confident that with this integration we will now be better positioned than ever to bring value to Canadian patients and healthcare providers.”
About Takeda Canada Inc.
Takeda Canada Inc. is the Canadian marketing and sales organization of Takeda Pharmaceutical Company Limited, headquartered in Japan. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
Additional information about Takeda Canada is available at www.takeda.com/en-ca.